# Yael P. Mossé

Source: https://onco.cc/people/yael-mosse/  
OnCo record `yael-mosse` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Discovered ALK mutations in neuroblastoma and led the trials bringing crizotinib and lorlatinib to children.

## Summary

Yael Mossé was first author of the 2008 discovery of ALK mutations in neuroblastoma and has led the clinical translation of ALK inhibition in children through the Children's Oncology Group and NANT consortium, including the phase 1 trials of crizotinib and lorlatinib and the addition of lorlatinib to front-line high-risk neuroblastoma therapy in COG ANBL1531. She leads the developmental therapeutics programme at CHOP.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: paediatric; neuroblastoma; alk
- Role: Professor of Pediatrics and Patricia Brophy Endowed Chair in Neuroblastoma Research, Children's Hospital of Philadelphia
- Specialisms: Neuroblastoma; ALK-targeted therapy; Paediatric drug development; Precision oncology

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Mosse%20YP%5BAuthor%5D%20neuroblastoma%20ALK

## Connected records

- cancers: [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [ALK](https://onco.cc/targets/alk/)
- drugs: [Lorlatinib](https://onco.cc/drugs/lorlatinib/)
- institutions: [Children's Hospital of Philadelphia](https://onco.cc/institutions/chop/)
- trials: [COG ANBL1531](https://onco.cc/trials/anbl1531/)

---
JSON: https://onco.cc/api/v1/entities/yael-mosse.json